Avita Medical Ltd (RCEL)

[Deetew]

-CEO confident of FDA approvals.
-June 7 soft tissue approval expected.
-June 17 vitiligo approval expected.
-current burns target market: 25,000
-post soft tissue approval target market: 145,000
-145,000/25,000= 5.8 multiple
-post vitiligo launch target market: 645,000
-645,000/25,000= 25.8 multiple
-70 reps now. More cost effective hiring early.
-marketing for soft tissue to begin right after approval.
-Recell Go enables international and vitiligo
-Recell Go launches ASAP after January 1, 2024 approval.
-Recell Go ESG-friendly
-International expansion details in Q4 2023
-Q1 2025 breakeven of burns and soft tissue with $30+ million remaining for vitiligo and international
-Q3 2023 is peak expenses. Expenses to decline after that.
-Chief Commercial Officer is no longer an expense and the role will not be replaced.
-Company looking for partner in Australia; this is priority.
-soft tissue promotion will be launched in 70+ hospitals in Q2.
-83% margins expected to grow as volumes increase
-Shelf offering is not an actual offering. It’s preparation for offering. Replaces previous shelf offering. Structures company to be flexible.
-30% of burns market is in trauma centers and accessible after soft tissue approval.